{"id":180515,"date":"2026-08-03T11:17:11","date_gmt":"2026-08-03T05:47:11","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=180515"},"modified":"2026-08-03T11:17:12","modified_gmt":"2026-08-03T05:47:12","slug":"sun-pharma-q1-results-fy27-pat-rs-2910-cr","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/","title":{"rendered":"Sun Pharma Q1 Results FY27: PAT at Rs 2,910 Cr for June 2026 Quarter"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Sun Pharma Q1 FY27: PAT Rs 2,910 Cr, +26.41% YoY. Revenue Rs 15,299 Cr, +10.46% YoY. Stock at Rs 1,987 (down 0.18%).<\/em><\/p>\n<p>The Sun Pharma Q1 results FY27 show consolidated revenue of Rs 15,299 Cr for the quarter ended 30 June 2026, +10.46% from Rs 13,851 Cr in Q1 FY26, as <a href=\"https:\/\/univest.in\/stocks\/sunpharma\/sun-pharmaceutical-industries-ltd-share-price-today\">Sun Pharma<\/a> reported its numbers on 31 July 2026.<\/p>\n<p>Sun Pharma posted a net profit (PAT) of Rs 2,910 Cr for the quarter, against Rs 2,302 Cr a year earlier. Shares traded around Rs 1,987 on the NSE, down 0.18% on the day, as investors weighed the print against trends in the pharmaceuticals sector. Here is a full breakdown of the financial highlights, key business factors, dividend status, outlook and risks.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=sun-pharma-q1-fy27-results\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Sun_Pharma_Q1_Results_FY27_Financial_Highlights\" title=\"Sun Pharma Q1 Results FY27 Financial Highlights\">Sun Pharma Q1 Results FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Sun_Pharma_Q1_FY27_Performance_Analysis\" title=\"Sun Pharma Q1 FY27 Performance Analysis\">Sun Pharma Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Sun_Pharma_Q1_FY27_Key_Business_Factors\" title=\"Sun Pharma Q1 FY27: Key Business Factors\">Sun Pharma Q1 FY27: Key Business Factors<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#1_Revenue_Growth_Trajectory\" title=\"1. Revenue Growth Trajectory\">1. Revenue Growth Trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#2_Gross_Margin_and_Cost_Trends\" title=\"2. Gross Margin and Cost Trends\">2. Gross Margin and Cost Trends<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#3_Bottom_Line_and_Earnings_Quality\" title=\"3. Bottom Line and Earnings Quality\">3. Bottom Line and Earnings Quality<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Sun_Pharma_Outlook_for_FY27\" title=\"Sun Pharma Outlook for FY27\">Sun Pharma Outlook for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Sun_Pharma_Stock_Performance_After_the_Results\" title=\"Sun Pharma Stock Performance After the Results\">Sun Pharma Stock Performance After the Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Key_Risks\" title=\"Key Risks\">Key Risks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#1_Margin_and_Input_Cost_Risk\" title=\"1. Margin and Input Cost Risk\">1. Margin and Input Cost Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#2_Execution_and_Working_Capital_Risk\" title=\"2. Execution and Working Capital Risk\">2. Execution and Working Capital Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#3_Macro_and_Sector_Risk\" title=\"3. Macro and Sector Risk\">3. Macro and Sector Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Frequently_Asked_Questions_on_Sun_Pharma_Q1_Results_FY27\" title=\"Frequently Asked Questions on Sun Pharma Q1 Results FY27\">Frequently Asked Questions on Sun Pharma Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#When_were_the_Sun_Pharma_Q1_results_FY27_announced\" title=\"When were the Sun Pharma Q1 results FY27 announced?\">When were the Sun Pharma Q1 results FY27 announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#What_is_the_PAT_in_Sun_Pharmas_Q1_FY27_results\" title=\"What is the PAT in Sun Pharma&#8217;s Q1 FY27 results?\">What is the PAT in Sun Pharma&#8217;s Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#What_was_the_revenue_in_Sun_Pharmas_Q1_FY27_results\" title=\"What was the revenue in Sun Pharma&#8217;s Q1 FY27 results?\">What was the revenue in Sun Pharma&#8217;s Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Did_Sun_Pharma_declare_a_dividend_with_the_Q1_FY27_results\" title=\"Did Sun Pharma declare a dividend with the Q1 FY27 results?\">Did Sun Pharma declare a dividend with the Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#What_is_the_outlook_for_Sun_Pharma_after_Q1_FY27\" title=\"What is the outlook for Sun Pharma after Q1 FY27?\">What is the outlook for Sun Pharma after Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#How_did_the_stock_react_to_Sun_Pharmas_Q1_FY27_results\" title=\"How did the stock react to Sun Pharma&#8217;s Q1 FY27 results?\">How did the stock react to Sun Pharma&#8217;s Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-q1-results-fy27-pat-rs-2910-cr\/#Is_Sun_Pharma_a_good_buy_after_the_Q1_FY27_results\" title=\"Is Sun Pharma a good buy after the Q1 FY27 results?\">Is Sun Pharma a good buy after the Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_Q1_Results_FY27_Financial_Highlights\"><\/span><strong>Sun Pharma Q1 Results FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below summarises Sun Pharma&#8217;s consolidated numbers for the quarter against the year ago period.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q1 FY27 (Jun 2026)<\/th>\n<th>Q1 FY26 (Jun 2025)<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>Rs 15,299 Cr<\/td>\n<td>Rs 13,851 Cr<\/td>\n<td>+10.46%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit<\/td>\n<td>Rs 3,678 Cr<\/td>\n<td>Rs 3,601 Cr<\/td>\n<td>+2.16%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit Margin<\/td>\n<td>24.0%<\/td>\n<td>26.0%<\/td>\n<td>-2.0 pts<\/td>\n<\/tr>\n<tr>\n<td>Net Profit (PAT)<\/td>\n<td>Rs 2,910 Cr<\/td>\n<td>Rs 2,302 Cr<\/td>\n<td>+26.41%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit Margin<\/td>\n<td>19.0%<\/td>\n<td>16.6%<\/td>\n<td>+2.4 pts<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_Q1_FY27_Performance_Analysis\"><\/span><strong>Sun Pharma Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Revenue growth was the standout number for the quarter. Sales rose +10.46% year on year to Rs 15,299 Cr, up from Rs 13,851 Cr in the year ago period, as demand held firm through the June quarter.<\/p>\n<p>Cost pressures show up clearly in the release, with gross profit changing +2.16% year on year to Rs 3,678 Cr (24.0% margin) even as the topline moved differently, pointing to margin compression during the period.<\/p>\n<p>The bottom line followed through on the operating performance. Net profit increased +26.41% year on year to Rs 2,910 Cr, up from Rs 2,302 Cr in Q1 FY26, translating the quarter&#8217;s operating trends into a stronger PAT print.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_Q1_FY27_Key_Business_Factors\"><\/span><strong>Sun Pharma Q1 FY27: Key Business Factors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Revenue_Growth_Trajectory\"><\/span><strong>1. Revenue Growth Trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sun Pharma reported revenue of Rs 15,299 Cr for the June 2026 quarter against Rs 13,851 Cr in the year ago period, a change of +10.46%. This pace of change is a primary swing factor behind the quarter&#8217;s numbers, and investors typically track whether it holds up in the following quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Gross_Margin_and_Cost_Trends\"><\/span><strong>2. Gross Margin and Cost Trends<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gross profit moved from Rs 3,601 Cr in Q1 FY26 to Rs 3,678 Cr in Q1 FY27, a change of +2.16%. In the pharmaceuticals sector, this line is sensitive to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets, and this quarter&#8217;s numbers reflect how Sun Pharma managed that balance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Bottom_Line_and_Earnings_Quality\"><\/span><strong>3. Bottom Line and Earnings Quality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net profit moved from Rs 2,302 Cr in Q1 FY26 to Rs 2,910 Cr this quarter, up +26.41%. On a reported basis this is the figure that flows through to earnings per share, and it is usually the first number investors check.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Specific dividend information was not confirmed as part of this results snapshot. Investors should check the official exchange filing on the NSE or BSE website, or track the Univest Screener, for the latest dividend announcement, record date and payment date from Sun Pharma.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_Outlook_for_FY27\"><\/span><strong>Sun Pharma Outlook for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This quarter sets the tone for the rest of FY27. If the growth in revenue and improvement in net profit persist, analysts are likely to revisit their FY27 estimates for Sun Pharma. Investors should also watch input costs and demand trends in the pharmaceuticals sector through the year.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_Stock_Performance_After_the_Results\"><\/span><strong>Sun Pharma Stock Performance After the Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sun Pharma shares traded around Rs 1,987 on the NSE, down 0.18% around the time the results were in focus. The 52 week trading range was not confirmed as part of this snapshot; investors can check the live 52 week high and low, along with technical levels, on the Univest Screener before making any trading decision.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Sun Pharma live share price and upcoming quarterly results.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks\"><\/span><strong>Key Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors reading through Sun Pharma&#8217;s numbers should also weigh the following risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Margin_and_Input_Cost_Risk\"><\/span><strong>1. Margin and Input Cost Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Being in the pharmaceuticals sector, Sun Pharma remains exposed to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets. A reversal in the trend seen this quarter could pressure margins in coming quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Execution_and_Working_Capital_Risk\"><\/span><strong>2. Execution and Working Capital Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Execution risk around working capital, receivables and order timelines can cause quarter to quarter volatility in reported numbers, so this quarter&#8217;s trends should be read over a few quarters rather than in isolation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Macro_and_Sector_Risk\"><\/span><strong>3. Macro and Sector Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Broader macro factors including interest rates, currency movements and demand cycles in the pharmaceuticals sector could influence how sustainable this quarter&#8217;s trends prove to be over FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Sun Pharma Q1 results FY27 show revenue of Rs 15,299 Cr and Rs 2,910 Cr for the quarter, against Rs 13,851 Cr and Rs 2,302 Cr in Q1 FY26. Revenue growth and a stronger bottom line were the two moving parts this quarter. Investors tracking Sun Pharma should watch the next few quarters for confirmation of this trend and consult a SEBI-registered advisor before making investment decisions based on these numbers.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Sun_Pharma_Q1_Results_FY27\"><\/span><strong>Frequently Asked Questions on Sun Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_the_Sun_Pharma_Q1_results_FY27_announced\"><\/span><strong>When were the Sun Pharma Q1 results FY27 announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> They reflect the quarter ended 30 June 2026, with the data reported as of 31 July 2026. Investors should confirm the exact board meeting date from the official NSE or BSE filing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PAT_in_Sun_Pharmas_Q1_FY27_results\"><\/span><strong>What is the PAT in Sun Pharma&#8217;s Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PAT stood at Rs 2,910 Cr, compared with Rs 2,302 Cr in Q1 FY26, a change of +26.41%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_revenue_in_Sun_Pharmas_Q1_FY27_results\"><\/span><strong>What was the revenue in Sun Pharma&#8217;s Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue came in at Rs 15,299 Cr for the quarter, a change of +10.46%, compared with Rs 13,851 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Sun_Pharma_declare_a_dividend_with_the_Q1_FY27_results\"><\/span><strong>Did Sun Pharma declare a dividend with the Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dividend details were not confirmed as part of this results snapshot. Check the latest exchange filing on NSE or BSE, or the Univest Screener, for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_outlook_for_Sun_Pharma_after_Q1_FY27\"><\/span><strong>What is the outlook for Sun Pharma after Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Analysts will track whether the growth in revenue and improvement in profit continue into the September 2026 quarter, along with input cost and demand trends in the pharmaceuticals sector.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_the_stock_react_to_Sun_Pharmas_Q1_FY27_results\"><\/span><strong>How did the stock react to Sun Pharma&#8217;s Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Shares traded around Rs 1,987 on the NSE, down 0.18% as the numbers came into focus.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Sun_Pharma_a_good_buy_after_the_Q1_FY27_results\"><\/span><strong>Is Sun Pharma a good buy after the Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The quarter shows a net profit of Rs 2,910 Cr on revenue of Rs 15,299 Cr. This article is for educational purposes only and is not investment advice. Consult a SEBI-registered advisor before making any investment decision.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sun Pharma Q1 results FY27: revenue Rs 15,299 Cr (+10.46% YoY), PAT Rs 2,910 Cr. Full financial highlights, key factors and outlook for the June 2026 quarter.<\/p>\n","protected":false},"author":35,"featured_media":180514,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-180515","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["180514"],"_edit_lock":["1785736035:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Sun Pharma Q1 FY27 Results: PAT Rs 2,910 Cr, Revenue Rs 15,299 Cr"],"rank_math_description":["Sun Pharma Q1 results FY27: revenue Rs 15,299 Cr (+10.46% YoY), PAT Rs 2,910 Cr. Full financial highlights, key factors and outlook for the June 2026 quarter."],"rank_math_focus_keyword":["Sun Pharma Q1"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["32803"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/sun-pharma-q1-results-fy27-pat-rs-2910-cr.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/180515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=180515"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/180515\/revisions"}],"predecessor-version":[{"id":180529,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/180515\/revisions\/180529"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/180514"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=180515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=180515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=180515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}